{"id":2379,"date":"2015-11-12T09:50:52","date_gmt":"2015-11-12T09:50:52","guid":{"rendered":"http:\/\/nsbri.org\/?page_id=2379"},"modified":"2016-05-07T12:33:45","modified_gmt":"2016-05-07T12:33:45","slug":"eligibility","status":"publish","type":"page","link":"http:\/\/nsbri.org\/for-business\/get-assistance\/eligibility\/","title":{"rendered":"Eligibility"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text]\"SMARTCAP\"<\/p>\n

SMARTCAP Criteria<\/h2>\n

NSBRI seeks products that will enable safe and productive human space flight and can be implemented in the space environment. Generally, technologies of value in space flight address an important medical issue for astronauts and are small, power-efficient, non-invasive, and easy-to-use. To learn more about what makes a product appropriate for use in space, please review these brief summaries of SMARTCAP grant recipients: SMARTCAP Funded Technologies<\/a>.<\/p>\n

\u00a0<\/strong>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator border_width=”2″][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p>\n

Healthcare in Space<\/h2>\n

Successful applicants will present a product that may be refined for space utilization while expanding the company\u2019s addressable market on Earth. This fulfills NSBRI\u2019s mission of safeguarding the health of humans working in space as well as improving life on Earth.<\/p>\n

The constraints on health care in space are similar to those experienced in remote or under-resourced regions on Earth. Technology solutions must be largely non-invasive, user-friendly for non-expert operators, compact, lightweight, and consume minimal power, water or other resources.\u00a0Pharmacological agents should be shelf-stable for several years and require minimal preparation prior to administration. IT solutions must stand alone and not require Internet connectivity.<\/p>\n

NSBRI, through its integrated research\u00a0 program<\/a>, seeks products and technologies to mitigate adverse effects on the body resulting from environmental stressors in space. For example, radiation exposure can result in acute and\/or long-term effects. For humans to safely undertake long duration missions i.e., to Mars, countermeasures are needed that can help protect healthy tissue from damage. The NSBRI program also looks at ways to enhance countermeasures already in place for long missions. Information about the impact of space travel on humans may be found here: The Body in Space<\/a>.<\/p>\n

For a more complete description of risks associated with human space flight see www.nsbri.org\/research<\/u> <\/a>and http:\/\/humanresearchroadmap.nasa.gov\/<\/a><\/u>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator border_width=”2″][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p>\n

Programmatic Priorities<\/strong><\/h2>\n

During each grant cycle, NSBRI may elect to focus on one or more programmatic priorities and consider only applicants that address the targeted areas. For example, SMARTCAP 2016 focused exclusively on radiation countermeasures that may protect healthy tissues from radiation damage or mitigate the impact of radiation exposure. Addressing radiation safety is crtical for long duration missions. Each call for applications, typically issued approximately one month prior to the application deadline for that grant cycle, will specify any targeted programmatic priorities.<\/p>\n

For a more complete description of risks associated with human space flight see www.nsbri.org\/research<\/u><\/a> and http:\/\/humanresearchroadmap.nasa.gov\/<\/a><\/u>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator border_width=”2″][vc_column_text]<\/p>\n

Company & Product Requirements<\/h2>\n

To be considered, companies must be based in the U.S., have 500 or fewer employees, and have a product that has achieved a Product Readiness Level > 3 if a device or diagnostic and a Product Readiness Level > 6 if a molecular therapeutic; see below for a brief description of each Product Readiness Level (PRL).[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator border_width=”2″][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p>\n

Product Readiness Levels (PRL)<\/h2>\n

PRL1: Market need and technology requirements identified
\nPRL2: Concept formulated and prototype designed
\nPRL3: Critical function and\/or proof-of-concept achieved
\nPRL4: Validation\/demonstration through user testing
\nPRL5: Validation\/demonstration in target population
\nPRL6: Regulatory studies in progress, if required
\nPRL7: Fabricated\/integrated in a production environment
\nPRL8: Regulatory approval (if required)
\nPRL9: Market ready
\nDesirable Projects<\/p>\n

The SMARTCAP grant should enable achievement of at least one key milestone on the commercialization pathway. Examples of desirable projects include:<\/p>\n